|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ling V, Gerlach J and Kartner N: Multidrug
resistance. Breast Cancer Res Treat. 4:89–94. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gottesman MM: Mechanisms of cancer drug
resistance. Annu Rev Med. 53:615–627. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Luqmani YA: Mechanisms of drug resistance
in cancer chemotherapy. Med Prin Pract. 14(Suppl 1): S35–S48.
2005.
|
|
5
|
Wu G, Qin XQ, Guo JJ, Li TY and Chen JH:
AKT/ERK activation is associated with gastric cancer cell
resistance to paclitaxel. Int J Clin Exp Pathol. 7:1449–1458.
2014.PubMed/NCBI
|
|
6
|
Olson JM and Hallahan AR: p38 MAP kinase:
a convergence point in cancer therapy. Trends Mol Med. 10:125–129.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Adams JM and Cory S: The Bcl-2 protein
family: arbiters of cell survival. Science. 281:1322–1326. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dive C: Avoidance of apoptosis as a
mechanism of drug resistance. J Intern Med Suppl. 740:139–145.
1997.PubMed/NCBI
|
|
9
|
Yang M, Huang J, Pan HZ and Jin J:
Triptolide overcomes dexamethasone resistance and enhanced
PS-341-induced apoptosis via PI3k/Akt/NF-kappaB pathways in human
multiple myeloma cells. Int J Mol Med. 22:489–496. 2008.PubMed/NCBI
|
|
10
|
Meng GM, Wang W, Chai KQ, Yang SW, Li FQ
and Jiang K: Combination treatment with triptolide and
hydroxycamptothecin synergistically enhances apoptosis in A549 lung
adenocarcinoma cells through PP 2A-regulated ERK, p38 MAPKs and Akt
signaling pathways. Int J Oncol. 46:1007–1017. 2015.PubMed/NCBI
|
|
11
|
Wang ZP, Jin HF, Xu RD, Mei QB and Fan DM:
Triptolide downregulates Rac1 and the JAK/STAT3 pathway and
inhibits colitis-related colon cancer progression. Exp Mol Med.
41:717–727. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wada T and Penninger JM: Mitogen-activated
protein kinases in apoptosis regulation. Oncogene. 23:2838–2849.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bradham C and McClay DR: p38 MAPK in
development and cancer. Cell Cycle. 5:824–828. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Modi PK, Komaravelli N, Singh N and Sharma
P: Interplay between MEK-ERK signaling, cyclin D1 and
cyclin-dependent kinase 5 regulates cell cycle reentry and
apoptosis of neurons. Mol Biol Cell. 23:3722–3730. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huang WC and Hung MC: Induction of Akt
activity by chemotherapy confers acquired resistance. J Formos Med
Assoc. 108:180–194. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li C, Sun BQ and Gai XD: Compounds from
Chinese herbal medicines as reversal agents for
P-glycoprotein-mediated multidrug resistance in tumours. Clin
Transl Oncol. 16:593–598. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Guo Q, Nan XX, Yang JR, Yi L, Liang BL,
Wei YB, Zhu N, Hu SB, Zhang H, Luo Y and Xu YF: Triptolide inhibits
the multidrug resistance in prostate cancer cells via the
downregulation of MDR1 expression. Neoplasma. 60:598–604. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li H, Hui L, Xu W, Shen H, Chen Q, Long L
and Zhu X: Modulation of P-glycoprotein expression by triptolide in
adriamycin-resistant K562/A02 cells. Oncol Lett. 3:485–489.
2012.PubMed/NCBI
|
|
19
|
Chen YW, Lin GJ, Chuang YP, Chia WT, Hueng
DY, Lin CK, Nieh S and Sytwu HK: Triptolide circumvents
drug-resistant effect and enhances 5-fluorouracil antitumor effect
on KB cells. Anti-Cancer Drugs. 21:502–513. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xie CQ, Zhou P, Yuan F, Li X and Chen JW:
Screening out potential agents from traditional Chinese medicine
with anti-multidrug resistance tumor cells in vitro. Lishizhen Med
Mater Med Res. 7:1572–1574. 2015.(In Chinese).
|
|
21
|
Thompson N and Lyons J: Recent progress in
targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug
discovery. Curr Opin Pharmacol. 5:350–356. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Han J and Sun P: The pathways to tumor
suppression via route p38. Trends Biochem Sci. 32:364–371. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bogoyevitch MA, Ngoei KR, Zhao TT, Yeap YY
and Ng DC: c-Jun N-terminal kinase (JNK) signaling: recent advances
and challenges. Biochim Biophys Acta. 1804:463–475. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Katayama K, Yoshioka S, Tsukahara S,
Mitsuhashi J and Sugimoto Y: Inhibition of the mitogen-activated
protein kinase pathway results in the down-regulation of
P-glycoprotein. Mol Cancer Ther. 6:2092–2102. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Barancik M, Bohácová V, Kvackajová J,
Hudecová S, Krizanová O and Breier A: SB203580, a specific
inhibitor of p38-MAPK pathway, is a new reversal agent of
P-glycoprotein-mediated multidrug resistance. Eur J Pharm Sci.
14:29–36. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Guo X, Ma N, Wang J, Song J, Bu X, Cheng
Y, Sun K, Xiong H, Jiang G, Zhang B, et al: Increased p38-MAPK is
responsible for chemotherapy resistance in human gastric cancer
cells. BMC Cancer. 8:3752008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Krishna M and Narang H: The complexity of
mitogen-activated protein kinases (MAPKs) made simple. Cell Mol
Life Sci. 65:3525–3544. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yeh PY, Chuang SE, Yeh KH, Song YC, Ea CK
and Cheng AL: Increase of the resistance of human cervical
carcinoma cells to cisplatin by inhibition of the MEK to ERK
signaling pathway partly via enhancement of anticancer drug-induced
NF kappa B activation. Biochem Pharmacol. 63:1423–1430. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kao YT, Hsu WC, Hu HT, Hsu SH, Lin CS,
Chiu CC, Lu CY, Hour TC, Pu YS and Huang AM: Involvement of p38
mitogen-activated protein kinase in acquired gemcitabine-resistant
human urothelial carcinoma sublines. Kaohsiung J Med Sci.
30:323–330. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li Y, Li S, Han Y, Liu J, Zhang J, Li F,
Wang Y, Liu X and Yao L: Calebin-A induces apoptosis and modulates
MAPK family activity in drug resistant human gastric cancer cells.
Eur J Pharmacol. 591:252–258. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Burris HA III: Overcoming acquired
resistance to anticancer therapy: focus on the PI3K/AKT/mTOR
pathway. Cancer Chemother Pharmacol. 71:829–842. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen KF, Chen HL, Tai WT, Feng WC, Hsu CH,
Chen PJ and Cheng AL: Activation of phosphatidylinositol
3-kinase/Akt signaling pathway mediates acquired resistance to
sorafenib in hepatocellular carcinoma cells. J Pharmacol Exp Ther.
337:155–161. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu BN, Yan HQ, Wu X, Pan ZH, Zhu Y, Meng
ZW, Zhou QH and Xu K: Apoptosis induced by benzyl isothiocyanate in
gefitinib-resistant lung cancer cells is associated with Akt/MAPK
pathways and generation of reactive oxygen species. Cell Biochem
Biophys. 66:81–92. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Galoian K, Temple HT and Galoyan A: mTORC1
inhibition and ECM-cell adhesion-independent drug resistance via
PI3K-AKT and PI3K-RAS-MAPK feedback loops. Tumour Biol. 33:885–890.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Frenzel A, Grespi F, Chmelewskij W and
Villunger A: Bcl2 family proteins in carcinogenesis and the
treatment of cancer. Apoptosis. 14:584–596. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Scorrano L and Korsmeyer SJ: Mechanisms of
cytochrome c release by proapoptotic BCL-2 family members. Biochem
Biophys Res Commun. 304:437–444. 2003. View Article : Google Scholar : PubMed/NCBI
|
